FDA recall record

Park Avenue Compounding Fentanyl citrate, 2 mcg / ml / Ropivacaine, 0.2% in NS 150 mL, CII recall — FDA D-0178-2026

CGMP Deviations: Revised interpretation of Acceptable Quality Level (AQL) results.

Class IIclassification
D-0178-2026official record ID
Nov 26, 2025report date

Recall record at a glance

Official recordD-0178-2026
CategoryDrug Recalls
ClassificationClass II
FDA record statusOngoing
Recalling firmPark Avenue Compounding
Report dateNov 26, 2025
Recall initiation dateSep 23, 2025
Quantity189 bags
LocationSaint Louis, MO, United States

Official product description

Fentanyl citrate, 2 mcg / ml / Ropivacaine, 0.2% in NS 150 mL, CII, 150 mL bag, Rx Only, Park Avenue Compounding, 3662 Park Ave, Saint Louis, MO, 63110, NDC 83863-4272-1.

Why the product was recalled

CGMP Deviations: Revised interpretation of Acceptable Quality Level (AQL) results.

Distribution information

Distributed in Missouri

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.